SHAPING THE FUTURE OF EXPERIMENTAL BIOLOGY, MEDICINE AND DRUG SCREENING
Living tissues are composed of a heterogeneous population of individual cells, which can differ dramatically from each other. These differences can have important consequences for the health and propagation of the entire population. To better study disease and aid in drug development, an in-depth analysis of cell behavior and physiological responses can best be accomplished with single-cell data.
Our mission is to redefine the approach to cell biology, and drug development by providing miniaturized instrumentation for single-cell investigations. The company is a world leader and pioneer in open-volume microfluidics for the life sciences, and holds a strong IP and patent position with five different patent families in the estate.
Our devices offer unprecedented data quality, throughput, resolution, and speed at affordable prices together with the capability to generate unique and critical data from single cells.
The BioPen is the first single-cell lab-on-a-tip tool for the life sciences sector and is used by leading universities and national health laboratories globally.
The Dynaflow Resolve system is considered by many to be the best secondary ion channel screening platform on the market. Launched in 2004, the Dynaflow platform is an established product with global big pharma and biotech companies as customers.
We are truly excited to be part of the technology transformation in medicine and biology towards smarter, more efficient, less resource-consuming, and environmentally friendly new experimental and drug screening practices that also minimizes the use of experimental animals.
Fluicell is a public company founded in 2012, and is based in Gothenburg, Sweden.